Correction to: Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants: Myocardial infarction with VKAs, aspirin or DOACS (British Journal of Clinical Pharmacology, (2017), 83, 8, (1835-1843), 10.1111/bcp.13264);Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants

British Journal of Clinical Pharmacology

Volumn 83, Issue 8, 2017, Pages 1835-1843

  Stolk, Leo M ^a   de Vries, Frank ^a,b,c   Ebbelaar, Chiel ^c   de Boer, Anthonius ^c   Schalekamp, Tom ^c   Souverein, Patrick ^c   ten Cate Hoek, Arina ^a   Burden, Andrea M ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

anticoagulants; cardiovascular pharmacology; pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG POTENCY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL HISTORY; MEDICAL RECORD; MEDICAL SPECIALIST; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANTAGONISTS AND INHIBITORS; HEART INFARCTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; STROKE; VITAMIN K;

EID: 85016037105     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.14001     Document Type: Erratum

References (30)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44 (Database Issue): D1054–D1068.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
6. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381–2391.
7. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298–3304.
8. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
9. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 2012; 125: 669–676.
10. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397–402.
11. Loffredo L, Perri L, Del Ben M, Angelico F, Violi F. New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Intern Emerg Med 2015; 10: 499–506.
12. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 2013; 9: 599–615.
13. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013; 112: 1973–1979.
14. Loffredo L, Perri L, Violi F. Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials. Int J Cardiol 2015; 178: 8–9.
15. Tornyos A, Kehl D, D'Ascenzo F, Komocsi A. Risk of myocardial infarction in patients with long-term non-vitamin K antagonist oral anticoagulant treatment. Prog Cardiovasc Dis 2016; 58: 483–494.
16. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014; 127: 1172–8 e5.
17. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. Comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290–1298.
18. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 4: e001798.
19. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264–2273.
20. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157–164.
21. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37: 1145–1153.
22. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research Datalink (CPRD). Int J Epidemiol 2015; 44: 827–836.
23. Davis EM, Packard KA, Knezevich JT, Campbell JA. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011; 31: 975–1016.
24. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004; 364: 937–952.
25. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the Management of Patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257–e354.
26. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015; 313: 1950–1962.
27. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the general practice research database. BMJ Open 2012; 2: e001768.
28. Ben Freedman S, Gersh BJ, Lip GY. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J 2015; 36: 653–656.
29. Jones C, Pollit V, Fitzmautice D, Cowan C. Updated NICE guideline: management of atrial fibrillation. Expert Rev. Cardiovasc Ther 2014; 12: 1037–1040.
30. Knottenbelt C, Brennan PJ, Meade TW. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med 2002; 162: 881–886.